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Abstract     
Background: The progress of scientific research gives new tracks to be exploited for the management 
of the colorectal cancers whose the molecular profile study became fundamental. Aim: the aim of this 
study was to compare the management of the colorectal cancer in our patients to the current 
international recommendations.  
Subjects and methods: In a retrospective study, we analysed 256 files between January, 2015 and 
September 2019. All the adenocarcinoma of colon and rectum were included.  
Our patients were divided into two groups: 161 patients with colorectal cancer (63%) and 95 patients 
with rectum cancer (37%). We studied if the management of the disease was actually compliant to the 
international recommendations. 
Results: Our study showed that the colorectal cancer occured most frequently in young population,  
with 45,5% in patients aged more than 60 years, 44% between 40 -60 years and 10 were  under 40 
years. The tumor was in T3 or more stage in 40,3% for colon cancer and 68,4% for rectum cancer. 
Elsewhere, none of the patients benefited from a molecular profile study of his tumor.  
Discussion:The colorectal cancer is diagnosed  in relatively young population with 54,5% of patients 
aged less than 60 years among whom 10% are less than 40, which explains the diagnostic delay. This 
delay is also due to the lack of a screening in general population and  high risk subjects. Moreover, the 
absence of  a molecular examination has a negative impact on the treatment and on the screening in 
the  apparented,  especially in case of tumor with micro satellite instability. 
Conclusion: In order to improve the prognosis of the colorectal cancers in our patients, a screening 
adapted to the groups at risk has to be implemented and a molecular profil examination achived so 
that evolution and therapeutics perspectives could be set. 
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1. Introduction 
Colorectal cancers (CRC) are common throughout the world with over 1 million 
cases and 500,000 deaths [1] per year. They occupy the third place among cancers 
[2].  However, the incidence of these cancers has decreased over the past four 
decades [3]  particularly in the USA, thanks to endoscopic screening. It should be 
noted that it is the cancers of the left colon that have decreased while those of the 
right colon have remained stable. CRC is a serious disease due to its digestive 
location with its nutritional impact and its functional impact for cancers of the 
rectum, close to the anal sphincter. Adenocarcinomas (ADK) are the most common 
cancers on this segment of the digestive tract. This histopathological type is 
heterogeneous with a different therapeutic response and course. 
Immunohistochemistry and molecular biology have made it possible to define the 
different biological profiles of colorectal cancers, the mechanisms of carcinogenesis, 
the different signaling pathways, which has led to the development of increasingly 
effective targeted therapies. For proper management, it is essential to have certain 
informations, mainly the one concerning the presence of a mutation in one or more 
genes of the DNA mismatch repair system (MMR system). Indeed, adenocarcinomas 
presenting this abnormality are more frequent on the right colon; they are 




distinguished from left colon ADKs in terms of precancerous lesions, prognosis, 
epidemiology and response to medical treatment. 
5% of CRC are hereditary and 30% occur in a context of family aggregation. In 
addition to an adequate epidemiological investigation, screening adapted to the risk 
group as well as the determination of the biological profile of the tumor should allow 
an effective management.             
2. Subjects and methods 
Through a retrospective study, we analyzed the files of 256 patients with CRC and 
treated in the general surgery department from January, 2015 to December, 2019. 
Inclusion criteria: all colon cancers (CC) and rectum Cancers (RC) in both sexes 
treated in the adult surgical department. 
Exclusion criteria: tumors of other histopathological types. 
Our workforce consisted of 161 colon ADKs, 20 were admitted urgently in an 
occlusion picture and 95 rectal cancers. The predominance was slightly male and 
more pronounced for RC (Ratio 1.31). There are 88 men against 73 women for the 
CCs and 54 men against 41 women for the RC. 
For colon cancers: 
Age: only 12 cases were recorded in subjects under the age of 40, ie 7% of colon 
cancers and 4.5% of all CRCs. The patients are over 60 years old in 52% of CCs (83 
patients); 41% of patients (66 patients) are between 40 and 60 years old and 92% are 
over 40 years old.  
The personal history: we find a notion of cancer in 8 patients and in 4 patients 
when assessing history familial; in 33 patients no history was specified. 
Localization: we find 49 sigmoid localizations, 22 left colic ones, 19 transverse 
colic and 71 right colic ones, according to the files. 
TNM classification: 54 patients presented with T3 tumors and 69 were T4. 
Differentiation: 79 cancers are well differentiated, 30 moderately differentiated and 
12 poorly differentiated. In 20 cases, the pathological study was imprecise. 
All patients had an extension assessment with a total colonoscopy, apart from the 
patients urgently operated and 30 patients scheduled cold in whom colonoscopy was 
incomplete or impossible, mainly due to the evolutionary stage of the lesion and poor 
preparation. 
For rectal cancers:  
Age: 34 patients are over 60 years old (37.5%), 47 patients between 40 and 60 years 
old (51.5%) and 14 are under 40 years old.  
Personal history : a personal history  was found in 11 cases but no family one.  
Localization: there were 35 cases on the lower rectum and an equal distribution for 
the middle and upper rectum. 
Colonoscopy: was only possible in 55 patients.  
TNM: 65 patients had T3 tumors or more.  
Differentiation: ADK was well differentiated in 57 patients, moderately 
differentiated in 11 and poorly differentiated in 08. In 10 cases the anatomopathology  
was inconclusive. 
3. Discussion  
In our series, relatively young and active subjects have the highest incidence of CRC. 
Through our analysis, it clearly appears that the diagnosis is most often late. Indeed, 




9.5% of CRCs are admitted and operated on emergency, in an occlusion picture. This 
emergency concerns 12% of CCs and 4.5% of RC. 
The diagnostic delay is confirmed by the pathological study. This delay in diagnosis 
is probably attributed to the occurrence of this cancer in a relatively young 
population which had been healthy until then, and without seriously affecting the 
general condition to get the patient and the physician attention. Regarding age, 
45.5% of CRCs are diagnosed in subjects over 60 years old, 44% of patients were 
between 40 and 60 years old and 10% under 40 years old. RCs are developing in an 
increasingly younger population: 66.5% are under 60 years old. Elsewhere, this 
diagnostic delay also seems to be due to the location of the tumor. Indeed, and 
according to international epidemiological studies, 2/3 of colonic cancers are located 
on the left colon knowing that the right colon concerns the segment going from the 
cecum to the splenic imprint, in other words, up to the left colic angle which is not 
included [4]. But in our series we find more ADK of the right colon (90 cases) than 
those of the left one (71 cases). These two locations are different, while patient 
records do not give great importance to such difference. The tumor location taken 
into account is surgical: etiopathogenically, the transverse colon does not exist, only 
the right colon and the left one are retained. 
serrated polyps, more frequent precancerous lesions on the right, are difficult to 
identify by optical or virtual colonoscopy. Our analysis showed that no screening has 
been scheduled for first-degree relatives of these patients operated on for CRC, 
whereas a colonoscopy is required in these subjects becoming at high risk. 
The diagnosis of CRC should no longer be based on clinical manifestations that are 
too often at an advanced stage, as the case is in our series. It is recommended by 
learned societies to offer screening in the general population said to be at average 
risk from the age of 50 years [5-8].  In the population at high risk, screening by 
optical endoscopy is necessary five years before the age of onset of cancer in the 
index case [9-11]. The same is true for chronic inflammatory bowel diseases that 
have progressed for 10 years with repeated flare-ups [12-14]. Syndromic cancers and 
polyposes are monitored by endoscopy according to the recommendations of learned 
societies [15].  
Indeed, CRC is one of the best preventable cancers. This cancer almost always 
develops on benign lesions such as adenomatous and serrated polyps. The Adenoma 
- Cancer sequence is currently well established [16]. Adenomatous polyps are the 
precursors of the majority of colorectal cancers [16]. Up to 80% of colorectal cancers 
result from the malignant transformation of an adenomatous polyp with a first stage 
of genesis of the adenoma followed by its growth and then its malignant 
degeneration [17]. The risk of cancerization increases crescendo with size, the 
presence of a villous component and with the presence of severe dysplasia which is 
more common in villous polyps [18, 19]. It is obvious that this risk of degeneration is 
greater when these risk factors are combined. These polyps are often the site of a 
Kras mutation. 
Serrated polyps, more common on the right, are a heterogeneous group made up of 
three different entities with different potential for malignant development. According 
to the WHO classification, a distinction is made between the hyperplastic polyp, the 
sessile serrated adenoma and the traditional serrated adenoma [20-22]. The latter two 
have a potential for degeneration, particularly the sessile serrated adenoma which 
represents 15 to 20% of serrated polyps and 90% of these polyps are located in the 
right colon [23].It is currently recognized as being the initial lesion of colorectal 
carcinogenesis according to a new path called “the serrated path” [21, 22, 24, 25] 
often with a BRAF mutation [26].  




Colorectal carcinogenesis is currently better known [27, 28] and three main 
molecular mechanisms of colorectal carcinogenesis are identified: 
1- Chromosomal instability [29, 30], known as CIN (Chromosomal INstability) 
or LOH (Loss Of Heterozygoty). This pathway, involved in at least 80% of 
CRC, is characterized by allelic losses associated with frequent mutations of 
tumor suppressor genes [30].    
2-  Micro satellite instability [29]  Involved in about 15% of CCRs. Cancers of 
the right colon are too often cancers with micro-satellite instability and called 
“MIS”. This instability can be germinal by mutation of one of the genes of the 
MMR (Mismatch Repair) system or by methylation. If 15% of sporadic CRCs 
are of IMS phenotype (dMMR), almost all CRCs in Lynch syndrome will be of 
this phenotype. Numerous studies have shown that the IMS stage II and III 
phenotype has a better prognosis than MSS tumors [31, 32]. This prognostic 
factor seems to be of interest to all stages with a significant reduction in the risk 
of death [33, 34]. 
3- Epigenetic instability [21, 35, 36] is the third mechanism more recently 
described, but which is dependent on the first two ones [36].  Here, there is no 
mutation, no deletion, no chromosomal instability and no micro satellite 
instability by mutation of the genes of the MMR system. DNA is methylated by 
adding a methyl group to a cytosine base (CpG islands). The DNA sequence is 
nor altered neither modified; we are talking about epigenetic phenomenon and 
not genetic one. Depending on the number of markers or the degree of 
methylation, CIMP-H tumors (for high) and CIMP-L tumors (for low) are 
defined. CIMP-H tumors are often associated with a mutation in the BRAF 
proto-oncogene (V600E) [37]. This mutation is too often found in sessile 
serrated adenomas (SSA) which are the precursors of these tumors. Indeed, 90% 
of tumors that develop from SSA have the BRAF mutation (V600E), whereas 
this mutation only very rarely [38]. or never [21]exists in adenomatous polyps.  
These findings have clinical implications:  
- It is important to look for the phenotype (dMMR), that is to say a lack of repair 
of DNA mismatches, and whose consequence is micro satellite instability and 
this by searching for protein extinction ("IHC" immunohistochemistry ) or by 
biological test. Among these tumors we should look for those belonging to 
Lynch syndrome defined by a mutation in one of the genes of the MMR system. 
In this case the patient and his relatives in the first degree become very high risk 
subjects requiring specific monitoring. The other tumors are unstable but 
sporadic. When IHC reveals a loss of expression of the MLH1 protein with or 
without PMS2 one, we must first look for a mutation of the BRAF gene and 
hypermethylation of the promoter of the MLH1 gene [39].  The presence of one 
of these abnormalities or of both of them indicates the sporadic character and the 
sequencing of the genes is no longer indicated saving time and money. 
The search for the unstable MSI phenotype will be carried out in case of CRC in 
a subject aged less than 70 years or in case of several cancers belonging to the 
spectrum in patients or their first degree relatives [39, 40].     
- The neoadjuvant treatment can be the cause of an extinction of the MSH6 
protein without there being any micro-satellite instability. 
- This same neoadjuvant treatment can give a complete histological response on 
an operative specimen. No test will be possible anymore. - The search for a 
BRAF and KRAS mutation is very important in case of metastatic colorectal 
disease in order to indicate a targeted therapy by anti EGFR (epidermal growth 




factor receptor) whose marketing authorization is conditioned by the absence of 
mutation [40].  
- Tumors of the right colon with MSI phenotype and BRAF mutation have an 
excellent prognosis.  
- On the other hand, colorectal tumors which develop along the serrated path, 
with CIMP-H methylation but MSS (satellite micro stability) are often 
diagnosed at an advanced stage.  
- CRCs of the CIMP-H and MSS phenotype with BRAF mutation have a bad 
prognosis, in particular for stages II, III and IV [41, 42] with a higher risk of 
death. 
- The MSI phenotype is rare in the rectum (about 3%) which does not dispense 
from the same scientific rigor when it comes to defining the biological profile of 
the tumor.  
- CRC at stage II and III IMS do not seem to benefit from chemotherapy with 
5FU alone, unlike MSS CRC. This molecule, 5 FU, would even be deleterious 
for CRCs at stage II IMS. IMS would be predictive of the ineffectiveness of 5FU 
alone in CRC with sporadic IMS and not in Lynch syndrome tumors [43].  
Determining the tumor IMS or MSS status has become essential to discuss the 
indication of adjuvant chemotherapy in a patient operated on for stage II CRC with 
bad prognostic factors. 
In our patients, the diagnosis of CRC was made by anatomopathological study of 
biopsies obtained via endoscopy. Analysis of our files shows that the biopsies are 
limited to 3 samples on average and fixed with formalin. Taking into account the 
cited elements of modern oncology, it is imperative to obtain, in the future, 10 to 15 
biopsies fixed and included in paraffin for molecular pathology. An 
immunohistochemical study or even a biological test looking for possible micro 
satellite instability must be carried out. The two tests are complementary. 
4. Conclusion 
The management of CRC requires specialists within a multidisciplinary team 
mastering the avenues of modern oncology. Treatment must be personalized. Each 
tumor has a specific biological profile. Immunohistochemical tests and molecular 
biology in addition to pathology data should allow a judicious therapeutic choice. 
This choice guarantees the best chances of recovery and survival for patients and 
allows us to spare them a heavy and expensive treatment and which is sometimes 
ineffective. The screening is the only way which allows a reduction of the mortality 
by colorectal cancer thanks to an early diagnosis as well as a reduction of the 
incidence of these tumors  thanks to the diagnosis and treatment of pre cancerous 
lesions. 
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